Development of enzalutamide for metastatic castration-resistant prostate cancer.
about
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.
P2860
Development of enzalutamide for metastatic castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development of enzalutamide for metastatic castration-resistant prostate cancer.
@en
type
label
Development of enzalutamide for metastatic castration-resistant prostate cancer.
@en
prefLabel
Development of enzalutamide for metastatic castration-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
Development of enzalutamide for metastatic castration-resistant prostate cancer.
@en
P2093
Mohammad Hirmand
Steve van Os
Suman Bhattacharya
P2860
P356
10.1111/NYAS.12846
P407
P577
2015-08-04T00:00:00Z